Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of the COVID-19 pandemic on cancer treatment and research.
Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, Saini ML, Verma S, Leone M, Aftimos P, Curigliano G. Saini KS, et al. Among authors: venkitaraman r. Lancet Haematol. 2020 Jun;7(6):e432-e435. doi: 10.1016/S2352-3026(20)30123-X. Epub 2020 Apr 24. Lancet Haematol. 2020. PMID: 32339482 Free PMC article. No abstract available.
Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.
de Las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, Romano M, Capelan M, Prasad R, Pattu P, Massard C, Portera C, Saini ML, Singh BP, Venkitaraman R, McNally R, Leone M, Grande E, Gupta S. de Las Heras B, et al. Among authors: venkitaraman r. Oncol Ther. 2020 Dec;8(2):171-182. doi: 10.1007/s40487-020-00124-2. Epub 2020 Aug 4. Oncol Ther. 2020. PMID: 32749634 Free PMC article.
Lobular neoplasia of the breast.
Venkitaraman R. Venkitaraman R. Breast J. 2010 Sep-Oct;16(5):519-28. doi: 10.1111/j.1524-4741.2010.00971.x. Epub 2010 Aug 4. Breast J. 2010. PMID: 20701604 Review.
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer.
Huddart R, Hafeez S, Lewis R, McNair H, Syndikus I, Henry A, Staffurth J, Dewan M, Vassallo-Bonner C, Moinuddin SA, Birtle A, Horan G, Rimmer Y, Venkitaraman R, Khoo V, Mitra A, Hughes S, Gibbs S, Kapur G, Baker A, Hansen VN, Patel E, Hall E; HYBRID Investigators. Huddart R, et al. Among authors: venkitaraman r. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):412-424. doi: 10.1016/j.ijrobp.2020.11.068. Epub 2020 Dec 11. Int J Radiat Oncol Biol Phys. 2021. PMID: 33316362 Free PMC article. Clinical Trial.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Jones RH, et al. Among authors: venkitaraman r. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035020 Free PMC article. Clinical Trial.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH. Howell SJ, et al. Among authors: venkitaraman r. Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4. Lancet Oncol. 2022. PMID: 35671774 Free PMC article. Clinical Trial.
61 results